OnKure Therapeutics, Inc.
$3.56+7.88%(+$0.26)
TickerSpark Score
54/100
93
Valuation
20
Profitability
15
Growth
84
Health
60
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OKUR research report →
52-Week Range48% of range
Low $1.91
Current $3.56
High $5.38
Companyonkuretherapeutics.com
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases.
- CEO
- Nicholas A. Saccomano
- IPO
- 2021
- Employees
- 46
- HQ
- Boulder, CO, US
Price Chart
+53.45% · this period
Valuation
- Market Cap
- $48.68M
- P/E
- -0.83
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- 2.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.02%
- ROIC
- -33.32%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-59,517,000 · -12.99%
- EPS
- $-4.40 · -11.39%
- Op Income
- $-62,950,000
- FCF YoY
- -1.38%
Performance & Tape
- 52W High
- $5.38
- 52W Low
- $1.91
- 50D MA
- $4.21
- 200D MA
- $3.15
- Beta
- 0.36
- Avg Volume
- 306.13K
Get TickerSpark's AI analysis on OKUR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | AI Biotechnology LLC | other | 0 |
| Mar 31, 26 | AI Biotechnology LLC | other | 5,640,222 |
| Apr 1, 26 | Saccomano Nicholas A | other | 330,000 |
| Apr 1, 26 | Leverone Jason A. | other | 110,000 |
| Apr 1, 26 | Hartley Dylan | other | 110,000 |
| Apr 1, 26 | Agresta Samuel | other | 110,000 |
| Mar 31, 26 | Ratcliffe Liam | other | 15,300 |
| Mar 31, 26 | Ratcliffe Liam | other | 0 |
| Mar 23, 26 | Saccomano Nicholas A | sell | 86 |
| Mar 23, 26 | Leverone Jason A. | sell | 301 |
Our OKUR Coverage
We haven't published any research on OKUR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OKUR Report →Similar Companies
TPST+4.49%
Tempest Therapeutics, Inc.
$1.86
KZR+0.00%
Kezar Life Sciences, Inc.
$7.29
FGEN-1.63%
FibroGen, Inc.
$9.07
PDSB+3.00%
PDS Biotechnology Corporation
$1.03
XLO+3.18%
Xilio Therapeutics, Inc.
$8.44
ATNM+1.74%
Actinium Pharmaceuticals, Inc.
$1.17
ALGS+8.11%
Aligos Therapeutics, Inc.
$5.60
MRSN+0.00%
Mersana Therapeutics, Inc.
$29.08